Indirubin-3'-monoxime rescues spatial memory deficits and attenuates β-amyloid-associated neuropathology in a mouse model of Alzheimer's disease
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Indirubin and its derivatives have been shown to possess potent inhibitory effects on cyclin-dependent protein kinase 5 and glycogen synthase kinase 3beta, two protein kinases involved in abnormal hyperphosphorylation of tau and amyloid precursor protein processing/beta-amyloid (Abeta) production. Here, we showed that systemic treatment of APP and presenilin 1 (PS1) transgenic mice, a robust Alzheimer's disease (AD) mouse model, with indirubin-3'-monoxime (IMX; 20mg/kg; 3 times weekly), for as little as 2months, significantly attenuated spatial memory deficits. This was accompanied by a marked decrease in several AD-like phenotypes, including Abeta deposition, tau hyperphosphorylation, accumulation of activated microglia and astrocytes around Abeta plaques, and loss of synaptophysin immunoreactivity. These findings suggest that IMX is a potential therapeutic agent to combat AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012 · cited 1×
“This scenario is consistent with previous studies showing that Aβ peptides directly induce synaptic loss and memory dysfunction (Knobloch and Mansuy, 2008) and that there is a correlation between learning deficit and Aβ plaques in a mouse model of AD (Yan et al., 1996).”
Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., Von Figura, K., & Van Leuven, F. (1998) · Nature · doi:10.1038/34910 · Cited by 1,818 · cited 1×
“Aβ peptides are generated by successive proteolysis of APP, a large transmembrane glycoprotein that is initially cleaved by the β-site APP-cleaving enzyme 1 (BACE1) and subsequently by γ-secretase in the transmembrane domain (De Strooper et al., 1998; Vassar et al., 1999; Edbauer et al., 2003).”
Microglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice
Hickman, S. E., Allison, E. K., & El Khoury, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0616-08.2008 · Cited by 1,329 · cited 2×
“, 2003), are down-regulated in APP/PS1 mice (Hickman et al., 2008), our next question was whether IMX reduces Aβ by increasing Aβ degradation enzymes.”
Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease
Itagaki, S., McGeer, P. L., Akiyama, H., Zhu, S., & Selkoe, D. (1989) · Journal of Neuroimmunology · doi:10.1016/0165-5728(89)90115-x · Cited by 940
Insulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation
Qiu, W. Q., Walsh, D. M., Ye, Z., Vekrellis, K., Zhang, J., Podlisny, M. B., Rosner, M. R., Safavi, A., Hersh, L. B., & Selkoe, D. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32730 · Cited by 812
Davies, C. A., Mann, D. M. A., Sumpter, P. Q., & Yates, P. O. (1987) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(87)90057-8 · Cited by 628 · cited 2×
“IMX attenuates loss of synaptophysin in APP/PS1 mice Post-mortem morphological studies on AD neuropathology have demonstrated significantly reduced synaptic connection in brain regions such as neocortex and hippocampus (Davies et al., 1987; Morrison and Hof, 2002).”
Neuron loss in APP transgenic mice
Calhoun, M. E., Wiederhold, K.-H., Abramowski, D., Phinney, A. L., Probst, A., Sturchler-Pierrat, C., Staufenbiel, M., Sommer, B., & Jucker, M. (1998) · Nature · doi:10.1038/27351 · Cited by 502 · cited 1×
“The percentage of neocortical or hippocampal volume occupied by Aβ (Aβ load) was determined by sampling through the entire neocortex or hippocampus and calculating thepercentage of points froma superimposed point grid that touched Aβ (Calhoun et al., 1998).”
Distribution, Levels, and Activity of Glycogen Synthase Kinase-3 in the Alzheimer Disease Brain
PEI, J.-J., TANAKA, T., TUNG, Y.-C., BRAAK, E., IQBAL, K., & GRUNDKE-IQBAL, I. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199701000-00007 · Cited by 371
A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo
Serenó, L., Coma, M., Rodríguez, M., Sánchez-Ferrer, P., Sánchez, M. B., Gich, I., Agulló, J. M., Pérez, M., Avila, J., Guardia-Laguarta, C., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.025 · Cited by 368
Weldon, D. T., Rogers, S. D., Ghilardi, J. R., Finke, M. P., Cleary, J. P., O’Hare, E., Esler, W. P., Maggio, J. E., & Mantyh, P. W. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-06-02161.1998 · Cited by 348
Association of Microglia with Amyloid Plaques in Brains of APP23 Transgenic Mice
Stalder, M., Phinney, A., Probst, A., Sommer, B., Staufenbiel, M., & Jucker, M. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65423-5 · Cited by 345 · cited 2×
“…treatment attenuates microglia and astrocyte activation A common feature of AD pathology is the abundance of reactive astrocytes and activated microglia in close proximity to Aβ plaques (Itagaki et al., 1989; Frautschy et al., 1998; Stalder et al., 1999; Matsuoka et al., 2001; Deacon et al., 2008).”
Dendritic Spine Loss and Synaptic Alterations in Alzheimer’s Disease
Knobloch, M., & Mansuy, I. M. (2008) · Molecular Neurobiology · doi:10.1007/s12035-008-8018-z · Cited by 296 · cited 2×
“This scenario is consistent with previous studies showing that Aβ peptides directly induce synaptic loss and memory dysfunction (Knobloch and Mansuy, 2008) and that there is a correlation between learning deficit and Aβ plaques in a mouse model of AD (Yan et al.”
Fischer, A., Sananbenesi, F., Pang, P. T., Lu, B., & Tsai, L.-H. (2005) · Neuron · doi:10.1016/j.neuron.2005.10.033 · Cited by 277
Yuskaitis, C. J., & Jope, R. S. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2008.10.014 · Cited by 240 · cited 4×
“Based on a recent finding that IMX inhibits microglial migration and activation in vitro (Yuskaitis and Jope, 2009), we hypothesize that this compound might be able to inhibit glial migration and/or activation in APP/PS1 mice.”
InfluentialPei, J.-J., Grundke-Iqbal, I., Iqbal, K., Bogdanovic, N., Winblad, B., & Cowburn, R. F. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00296-0 · Cited by 226 · cited 1×
“…unclear, two proline-directed serine/threonine kinases become the focus of molecular AD research: glycogen synthase kinase 3β (GSK3β) and cyclin-dependent kinase 5 (Cdk5), whose activities appear to be increased in the AD brain (Yamaguchi et al., 1996; Pei et al., 1997, 1998; Ding et al., 2008).”
Aplin, A. E., Gibb, G. M., Jacobsen, J. S., Gallo, J., & Anderton, B. H. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67020699.x · Cited by 201 · cited 2×
“In the AD brain, tau is hyperphosphorylated at more than 38 different sites, which interferes with the affinity of tau-microtubule binding (Aplin et al., 1996) and causes neurofibrillary tangle formation (Knafo et al.”
Wen, Y., Planel, E., Herman, M., Figueroa, H. Y., Wang, L., Liu, L., Lau, L.-F., Yu, W. H., & Duff, K. E. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5245-07.2008 · Cited by 145 · cited 2×
“Both kinases are involved in tau hyperphosphorylation (Ishiguro et al., 1992; Tsai et al., 1994; Michel et al., 1998) and APP processing/Aβ generation (Cruz et al., 2006; Uemura et al., 2007;Wen et al., 2008a, b).”
Widespread Changes in Dendritic Spines in a Model of Alzheimer's Disease
Knafo, S., Alonso-Nanclares, L., Gonzalez-Soriano, J., Merino-Serrais, P., Fernaud-Espinosa, I., Ferrer, I., & DeFelipe, J. (2009) · Cerebral Cortex · doi:10.1093/cercor/bhn111 · Cited by 132
Traffic at the intersection of neurotrophic factor signaling and neurodegeneration
Salehi, A., Delcroix, J.-D., & Mobley, W. C. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(02)00038-3 · Cited by 131
Frautschy, S. A., Horn, D. L., Sigel, J. J., Harris-White, M. E., Mendoza, J. J., Yang, F., Saido, T. C., & Cole, G. M. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-20-08311.1998 · Cited by 65
Cited by
Glycogen synthase kinase-3 signaling in Alzheimer's disease
Lauretti, E., Dincer, O., & Praticò, D. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118664 · Cited by 615
Lai, J.-L., Liu, Y.-H., Liu, C., Qi, M.-P., Liu, R.-N., Zhu, X.-F., Zhou, Q.-G., Chen, Y.-Y., Guo, A.-Z., & Hu, C.-M. (2017) · Inflammation · doi:10.1007/s10753-016-0447-7 · Cited by 471
GSK-3β, a pivotal kinase in Alzheimer disease
Llorens-MarÃtin, M., Jurado, J., Hernández, F., & Ãvila, J. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00046 · Cited by 451
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
Eldar-Finkelman, H., & Martinez, A. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00032 · Cited by 354
Diabetes mellitus and Alzheimer's disease: GSK-3β as a potential link
Zhang, Y., Huang, N.-Q., Yan, F., Jin, H., Zhou, S.-Y., Shi, J.-S., & Jin, F. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.11.015 · Cited by 301
“this was accompanied by a marked decrease in several AD-like phenotypes [115].”
Background
Metadata
- Authors
- Ding, Y., Qiao, A., & Fan, G.-H.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2010-08
- Volume
- 39
- Issue
- 2
- Pages
- 156-168
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W1995975927
- Cited by
- 75
- References
- 20
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.